178 related articles for article (PubMed ID: 26898841)
21. Intraperitoneal chemotherapy hyperthermia (HIPEC) for peritoneal carcinomatosis of ovarian cancer origin by fluid and CO2 recirculation using the closed abdomen technique (PRS-1.0 Combat): A clinical pilot study.
Sánchez-García S; Villarejo-Campos P; Padilla-Valverde D; Amo-Salas M; Martín-Fernández J
Int J Hyperthermia; 2016 Aug; 32(5):488-95. PubMed ID: 27056558
[TBL] [Abstract][Full Text] [Related]
22. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer.
Roviello F; Pinto E; Corso G; Pedrazzani C; Caruso S; Filippeschi M; Petrioli R; Marsili S; Mazzei MA; Marrelli D
J Surg Oncol; 2010 Nov; 102(6):663-70. PubMed ID: 20721959
[TBL] [Abstract][Full Text] [Related]
23. HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy.
McConnell YJ; Mack LA; Francis WP; Ho T; Temple WJ
J Surg Oncol; 2013 May; 107(6):591-6. PubMed ID: 23129533
[TBL] [Abstract][Full Text] [Related]
24. Re-admissions for delayed complications after cytoreductive surgery and HIPEC.
Spiliotis J; Argiriou EO; Vafias E; Manou V; Vaos N; Datsis A; Efstathiou E
Acta Chir Belg; 2016 Apr; 116(2):96-100. PubMed ID: 27385296
[TBL] [Abstract][Full Text] [Related]
25. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
26. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
[TBL] [Abstract][Full Text] [Related]
27. Hyperthermic intraperitoneal chemotherapy with cisplatin: Amifostine prevents acute severe renal impairment.
Bouhadjari N; Gabato W; Calabrese D; Msika S; Keita H
Eur J Surg Oncol; 2016 Feb; 42(2):219-23. PubMed ID: 26278017
[TBL] [Abstract][Full Text] [Related]
28. Peritoneal carcinomatosis in patients with gastric cancer, and the role for surgical resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy.
Kim KW; Chow O; Parikh K; Blank S; Jibara G; Kadri H; Labow DM; Hiotis SP
Am J Surg; 2014 Jan; 207(1):78-83. PubMed ID: 24157224
[TBL] [Abstract][Full Text] [Related]
29. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study.
Cashin PH; Graf W; Nygren P; Mahteme H
Eur J Surg Oncol; 2012 Jun; 38(6):509-15. PubMed ID: 22475555
[TBL] [Abstract][Full Text] [Related]
30. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
[TBL] [Abstract][Full Text] [Related]
31. Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.
Sin EI; Chia CS; Tan GHC; Soo KC; Teo MC
Int J Hyperthermia; 2017 Sep; 33(6):690-695. PubMed ID: 28540777
[TBL] [Abstract][Full Text] [Related]
32. Accuracy of MDCT in the preoperative definition of Peritoneal Cancer Index (PCI) in patients with advanced ovarian cancer who underwent peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC).
Mazzei MA; Khader L; Cirigliano A; Cioffi Squitieri N; Guerrini S; Forzoni B; Marrelli D; Roviello F; Mazzei FG; Volterrani L
Abdom Imaging; 2013 Dec; 38(6):1422-30. PubMed ID: 23744439
[TBL] [Abstract][Full Text] [Related]
33. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center.
Muñoz-Casares FC; Medina-Fernández FJ; Arjona-Sánchez Á; Casado-Adam Á; Sánchez-Hidalgo JM; Rubio MJ; Ortega-Salas R; Muñoz-Villanueva MC; Rufián-Peña S; Briceño FJ
Eur J Surg Oncol; 2016 Feb; 42(2):224-33. PubMed ID: 26673283
[TBL] [Abstract][Full Text] [Related]
34. Complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: Risk factors for ICU admission and morbidity prognostic score.
Malfroy S; Wallet F; Maucort-Boulch D; Chardonnal L; Sens N; Friggeri A; Passot G; Glehen O; Piriou V
Surg Oncol; 2016 Mar; 25(1):6-15. PubMed ID: 26979635
[TBL] [Abstract][Full Text] [Related]
35. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.
Di Giorgio A; Naticchioni E; Biacchi D; Sibio S; Accarpio F; Rocco M; Tarquini S; Di Seri M; Ciardi A; Montruccoli D; Sammartino P
Cancer; 2008 Jul; 113(2):315-25. PubMed ID: 18473354
[TBL] [Abstract][Full Text] [Related]
36. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
[TBL] [Abstract][Full Text] [Related]
37. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer.
Polom K; Roviello G; Generali D; Marano L; Petrioli R; Marsili S; Caputo E; Marrelli D; Roviello F
Int J Hyperthermia; 2016 May; 32(3):298-310. PubMed ID: 26984715
[TBL] [Abstract][Full Text] [Related]
38. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
[TBL] [Abstract][Full Text] [Related]
39. Risk factors of acute renal impairment after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chen CY; Chang HY; Lu CH; Chen MC; Huang TH; Lee LW; Liao YS; Chen VC; Huang WS; Ou YC; Lung FC; Wang TY
Int J Hyperthermia; 2020; 37(1):1279-1286. PubMed ID: 33198563
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
Eveno C; Passot G; Goéré D; Soyer P; Gayat E; Glehen O; Elias D; Pocard M
Ann Surg Oncol; 2014 Jun; 21(6):1792-800. PubMed ID: 24337648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
